Orion Therapeutics Email Formats

About Orion Therapeutics

The recent success of mRNA vaccines in the fight against COVID-19 has placed RNA-based pharmaceutical strategies center-stage in the biotech community. This medical milestone marks an inflection point in human history that will revolutionize the pharmaceutical industry from top-to-bottom, providing cures for the incurable and improving the overall quality of life for patients across the globe. However, the primary challenge hindering commercialization of these RNA drugs is the issue of DELIVERY. There are nearly 1500 nucleic acid-based drugs (RNA or DNA) currently in preclinical development for a wide range of disease applications including cancer, cardiovascular disease, HIV, Alzheimer's, and certain forms of blindness to name a few. Despite the extensive investment in these technologies over the last decade, only a handful of RNA drugs have been approved for human use. The major factor preventing translational success in these drug development programs is the lack of a safe, targeted, and efficacious delivery system for RNA drug payloads. The most successful delivery formulations to-date are represented by lipid nanoparticles (LNP) exemplified in mRNA vaccines developed by Pfizer-BioNTech and Moderna. These LNP technologies rely on unnatural lipid chemistries that limit utility of mRNA drug platforms and pipeline from a safety and efficacy standpoint. Also, many of our competitors within the non-viral RNA delivery space have been embroiled in litigation over intellectual property that is entangled in advanced LNP formulation processes. Orion has developed a targeted LNP delivery platform that packages and protects nucleic acid drug payloads for safe and effective use in human patients. Our delivery platform is agnostic to both RNA type/class and disease indication with nearly limitless utility in the RNA therapeutics and vaccine market.

View contact profiles from Orion Therapeutics